Publicaciones en las que colabora con Xavier Montalbán Gairín (33)

2023

  1. Association of Serum Neurofilament Light Chain Levels at Disease Onset with Disability Worsening in Patients with a First Demyelinating Multiple Sclerosis Event Not Treated with High-Efficacy Drugs

    JAMA Neurology, Vol. 80, Núm. 4, pp. 397-403

  2. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  3. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2018

  1. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates

    Multiple Sclerosis Journal, Vol. 24, Núm. 14, pp. 1843-1851

2016

  1. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

    Revista de Neurologia, Vol. 62, Núm. 12, pp. 559-569

2015

  1. Review of the novelties from the 2014 ECTRIMS-ACTRIMS joint congress, presented at the 7th post-ECTRIMS meeting (II)

    Revista de Neurologia, Vol. 61, Núm. 6, pp. 271-283

  2. Review of the novelties from the 2014 ectrims-actrims joint congress, presented at the 7th post-ectrims meeting (i)

    Revista de Neurologia, Vol. 61, Núm. 5, pp. 215-224

2014

  1. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS

    Multiple Sclerosis Journal, Vol. 20, Núm. 6, pp. 717-725

2012

  1. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

    Revista de neurologia, Vol. 54, Núm. 12, pp. 734-749

  2. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

    Revista de Neurologia, Vol. 54, Núm. 11, pp. 677-691

2011

  1. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: Five-year clinical trial follow-up

    Archives of Neurology, Vol. 68, Núm. 11, pp. 1421-1427

2010

  1. Multiple sclerosis epidemiological situation update: Pertinence and set-up of a population based registry of new cases in Catalonia

    Revista de Neurologia, Vol. 50, Núm. 10, pp. 623-633

  2. Progression on the multiple sclerosis functional composite in multiple sclerosis: What is the optimal cut-off for the three components?

    Multiple Sclerosis, Vol. 16, Núm. 7, pp. 862-867

2009

  1. A single-center, randomized, doubleblind, placebo-controlled study of interferon beta- I b on primary progressive and transitional multiple sclerosis

    Multiple Sclerosis, Vol. 15, Núm. 10, pp. 1195-1205

  2. The search for responsive clinical endpoints in primary progressive multiple sclerosis

    Multiple Sclerosis, Vol. 15, Núm. 6, pp. 715-720

2008

  1. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis

    Journal of Neurology, Vol. 255, Núm. 8, pp. 1136-1141

2006

  1. Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone

    Multiple Sclerosis, Vol. 12, Núm. 4, pp. 487-494

2004

  1. Corticosteroids, ibuprofen, and acetaminophen for IFNβ-1a flu symptoms in MS: A randomized trial

    Neurology, Vol. 63, Núm. 3, pp. 525-528

  2. Decreased MMP-9 production in primary progressive multiple sclerosis patients

    Multiple Sclerosis, Vol. 10, Núm. 4, pp. 376-380